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Abstract Increasing evidence suggests that intake of long-
chain polyunsaturated fatty acids (LCPUFA), especially
omega-3 LCPUFA, improves respiratory health early in life.
This review summarizes publications from 2009 through
July 2012 that evaluated effects of fish, fish oil or LCPUFA
intake during pregnancy, lactation, and early postnatal years
on allergic and infectious respiratory illnesses. Studies dur-
ing pregnancy found inconsistent effects in offspring: two
showed no effects and three showed protective effects of
omega-3 LCPUFA on respiratory illnesses or atopic derma-
titis. Two studies found that infants fed breast milk with
higher omega-3 LCPUFA had reduced allergic manifesta-
tions. Earlier introduction of fish improved respiratory
health or reduced allergy in four studies. Three randomized
controlled trials showed that providing LCPUFA during
infancy or childhood reduced allergy and/or respiratory
illness while one found no effect. Potential explanations
for the variability among studies and possible mechanisms
of action for LCPUFA in allergy and respiratory disease are
discussed.
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Introduction
Respiratory illnesses, both infectious and allergic, are a
major cause of morbidity in children. Around 95 % of
children have at least one acute respiratory infection in the
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first 3 years of life; 75 % have upper respiratory infections
(URI) [1, 2••]. Lower respiratory infections, especially
pneumonia, are associated with higher mortality, being the
leading cause of death in children under 5 years of age
worldwide [3]. Asthma is the most prevalent chronic illness
in childhood, affecting around 10 % and, in some countries,
up to 25 % of children [4]. Allergic manifestations, includ-
ing allergic rhinitis, asthma, and atopic dermatitis (AD,
often called atopic eczema or eczema), have been increasing
in the last several decades [4, 5].
Appropriate nutrition is critical early in life, when there is
a window of opportunity to support normal development
and function of the immune system [6–8]. The neonate has
several immunological immaturities, which include priming
interactions of antigen-presenting cells, cytotoxic T-cell
responses to infection, complement activity, and antibody
responses to antigen exposure, in addition to Th2-phenotype
polarization [9]. Th1 cytokines are involved in inflammato-
ry reactions directed to fight infections, whereas Th2 cyto-
kines are involved in antibody production, particularly IgE,
and are commonly associated with allergic reactions. Th1
and Th2 cytokines have mutually inhibitory functions [10].
The placental immunological milieu is switched towards a
Th2 phenotype to ensure that the maternal immune system
will not mount a Th1 response against the fetus. This also
affects the newborn who is skewed towards Th2 response
and needs to be redirected towards appropriate Th1 response
that allows protection from infectious diseases [8]. Immu-
nomodulatory components and nutrients in breast milk can
influence the maturation of the immune system, response to
infections, and development of atopic diseases; some of
these nutrients may also be delivered through other dietary
sources. Recently, research has focused on long-chain poly-
unsaturated fatty acids (LCPUFA) early in life as immuno-
modulatory nutrients potentially playing important roles in
prevention and resolution of respiratory illnesses and
allergy.
The LCPUFA of interest include the omega-3 (or n-3)
LCPUFA docosahexaenoic acid (DHA, 22:6n-3) and eico-
sapentaenoic acid (EPA, 20:5n-3) and the omega-6 (or n-6)
LCPUFA arachidonic acid (ARA, 20:4n-6). These LCPUFA
are synthesized endogenously from the precursors alpha-
linolenic acid (ALA, 18:3n-3) and linoleic acid (LA,
18:2n-6) through a series of elongation and desaturation
steps common to the omega-3 and omega-6 pathways [11].
This conversion, particularly for ALA to DHA, is ineffi-
cient, and endogenous production will not meet the require-
ments of all infants during rapid tissue growth and
development [12]. Research on LCPUFA early in life has
focused on their roles in neurodevelopment, because DHA
and ARA accumulate, especially during late pregnancy
through about 2 years postnatally, in uniquely high concen-
trations in brain gray matter [13]. DHA, EPA, and ARA
serve as important cell membrane components as well as
precursors for an extensive network of biologic mediators
with many effects in the body, including numerous roles in
immune function and inflammation [11].
Several expert bodies recommend including specific
amounts of LCPUFA in the diets of infants, children, and
their mothers [14–19]. Maternal LCPUFA intake impacts
delivery of these fatty acids to the infant via the placenta
before birth and via breast milk [14]. Several groups recom-
mend that pregnant and lactating women consume at least
200–250 mg DHA daily, which can be achieved by con-
suming fish, especially fatty fish like salmon, mackerel, and
tuna, or through dietary supplements like fish or algal oil
[14, 17–19]. Breast milk is the preferred sole source of
nutrition for infants through 4–6 months, with continued
breastfeeding to 12 months or longer. Breast milk from
mothers meeting recommended DHA intakes should pro-
vide sufficient LCPUFA supply. Experts recommend that
infants weaned from breastfeeding should consume a diet
with adequate amounts of added DHA and ARA, in a
balance similar to that typically found in breast milk
[15–19], and that diets should continue to provide sufficient
amounts of omega-3 LCPUFA through childhood and adult-
hood [17–19]. There are no specific recommendations for
ARA intake by children or adults, including pregnant and
nursing women, because diets are typically rich in LA,
which is readily converted to ARA to meet needs.
The association between omega-3 intake from fish or fish
oil supplements early in life and risk of allergy was evalu-
ated in a systematic review of studies through 2009 [20]. It
concluded that most epidemiological studies of fish intake in
pregnancy, infancy, or childhood found a protective effect of
fish on atopic outcomes, but the benefits of fish oil supple-
mentation were less clear. A 2009 critical review on the use
of omega-3 LCPUFA for treatment of inflammatory condi-
tions concluded that LCPUFA may be beneficial for treat-
ment of children with asthma [21]. In this paper, we review
additional studies published from 2009 through July 2012
that examine effects of fish, fish oil or LCPUFA intake
during pregnancy, lactation, and early postnatal years on
allergic and infectious respiratory illnesses.
Studies of LCPUFA and Respiratory Illness Early
in Life
Maternal LCPUFA Supply During Pregnancy
and/or Lactation
A 2005 review concluded that there is evidence that provid-
ing omega-3 LCPUFA during pregnancy may reduce devel-
opment or severity of allergic disease in the offspring [22].
More recent randomized controlled clinical trials (RCTs)
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that assessed effects of omega-3 LCPUFA or fatty fish
during pregnancy and/or lactation on infant outcomes relat-
ed to respiratory health, as well as studies that evaluated
associations between maternal diet or breast milk fatty acids
and infant allergic outcomes, are summarized in Table 1.
A large double-blind RCT of women supplemented with
400 mg DHA per day from algal oil or an LCPUFA-free
placebo from 18–22 weeks gestation through parturition
found that DHA reduced occurrence of parent-reported cold
symptoms (cough, phlegm, nasal congestion, nasal secretion)
in 1-month-old offspring [23•]. Maternal DHA supplementa-
tion also resulted in shorter duration of cough, phlegm and
wheezing at 1 month, other illnesses such as ear infection and
sore throat at 3 and 6 months, and nasal secretion, difficulty
breathing, fever, and rash, including diaper rash and AD, at
6 months, but increased duration of rash at 1 month, nasal
congestion at 3 months, and vomiting at 6 months. Overall,
this trial showed that DHA supplementation in pregnancy
improved respiratory health of young infants.
Another large double-blind RCT evaluated effects of fish
oil supplementation, providing 800 mg DHA and 100 mg
EPA daily versus placebo, from gestational week 21 until
delivery to women with offspring at high risk of allergy (i.e.
with a family history of allergy) [24]. There were no differ-
ences between groups in rates of respiratory tract infections,
allergic manifestations, or IgE-mediated food allergies
through 12 months of age. Maternal fish oil, however,
resulted in lower incidence of AD and sensitization to egg.
The authors note that longer follow-up would be of interest
because egg allergy has been associated with respiratory
allergy at later ages [25].
A recent RCT investigated whether adding fatty fish to the
diet of pregnant women altered their offspring’s neonatal
immune markers [26]. Women consuming less than two fatty
fish servings per month and not using fish oil supplements,
and whose infants were at high risk of allergy, were random-
ized to continue their habitual diet or add two portions of
salmon weekly (providing 3.45 g EPA plus DHA) to their
Table 1 Characteristics of studies evaluating the effects of LCPUFA during pregnancy and/or lactation on respiratory and related outcomes in
infants or young children
Author, year [Ref] Type of trial;
location







DHA group: 400 mg DHA
from algal oil (2 capsules/day)
18–22 weeks gestation
to delivery; follow-up at 1,
3, and 6 months of age
Parental reports of occurrence
and duration of illness symptoms










Omega-3 group: 800 mg DHA
and 100 mg EPA from fish
oil (3 capsules/day)
21 weeks gestation to
delivery; follow-up at 12
months of age
Diagnosis of IgE-associated allergic disease,
i.e., atopic dermatitis or food allergy with
sensitization (positive skin prick test to at









Fish group: two 150 g
portions of salmon per week
(3.45 g EPA plus DHA)
20 weeks gestation to
delivery; follow-up at 6
months of age
Cord blood fatty acids and mononuclear cell
cytokine and PGE2 production; leukocyte
phenotypes; serum total IgE at birth and 6











Omega-3 group: 1.6 g EPA




3–4 months); follow-up at
3, 6, and 12 months of age
Serum IgE for specific allergens at 3 and 12
months; IgE-associated atopic dermatitis;














Omega-3 group: 1.6 g EPA




up at 24 months of age
Serum IgE for specific allergens at 24 months;
cumulative incidence (0–24 months) of
positive skin prick tests, allergic symptoms,









(n02,679) at risk of
type 1 diabetes
None Follow-up at 5 years of age Maternal fatty acid intake by food frequency
questionnaire in 8th month of pregnancy;
asthma risk at 5 years







at risk of type 1
diabetes (n01,798
pairs)
None Follow-up at 5 years of age Maternal fatty acid intake by food frequency
questionnaire in 3rd month of lactation;








None Follow-up at 24 months of
age
Breast milk fatty acids at 1 month
postpartum; parent questionnaires on
atopic outcomes; serum total IgE and










with fish oil or
placebo capsules
High DHA group: breast milk
or preterm formula with
0.85–1 % fatty acids as DHA
From birth until expected
date of delivery; follow-up
at 18 months of age
Incidence of bronchopulmonary dysplasia;
structured parenteral interviews at 12 and 18
months about medical attention/treatment
for hay fever, atopic dermatitis, asthma, or
food allergy and any readmissions to hospital
Control: breast milk or
standard preterm formula
with 0.25–0.35 % DHA
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diet from gestational week 20 until delivery. While production
of some Th1 and Th2 cytokines was lower in cord blood
mononuclear cells from the salmon group, the changes did
not point to a specific protective pattern against allergy or
infections, and no significant differences were found in inci-
dence or severity of AD, wheeze, bronchiolitis, or chest infec-
tions or sensitization rates of 6-month-old infants.
In another RCT, women with infants at increased allergy
risk were randomized to receive a fish oil supplement pro-
viding 1.6 g EPA and 1.1 g DHA daily or placebo from
gestational week 25 through 3–4 months of lactation. Prev-
alence of IgE-associated food allergy and AD were signifi-
cantly lower at 12 months in offspring of the fish oil group
compared to control [27]. During the first 2 years, incidence
of IgE-associated food allergy or AD, or any IgE-associated
disease, as well as sensitization to egg, were significantly
lower in the fish oil group [28]. No differences were found
between groups in prevalence of asthma.
In two retrospective observational studies, relationships
were assessed between maternal fatty acid intake in preg-
nancy and in lactation and risk of asthma in 5-year-old
offspring, who were at high risk of type I diabetes [29,
30]. Maternal DHA or EPA intakes at the eighth month of
pregnancy or the third month of lactation were not associ-
ated with risk of childhood asthma, but lower intake of total
omega-3 PUFA (driven by lower ALA) during pregnancy
was. No association was seen between maternal fish intake
and risk of asthma, perhaps due to low fish intake of the
mothers. Low ARA intake during pregnancy was associated
with decreased risk of asthma, while low ALA intake was
associated with increased risk. The authors hypothesize that
the reduced risk associated with low ARA intake may be
explained by its role as a precursor of pro-inflammatory
eicosanoids, while low ALA may result in lower synthesis
of omega-3 LCPUFA, particularly EPA.
Several studies published before 2009 investigated rela-
tionships between breast milk LCPUFA and incidence of
asthma or other allergic or respiratory conditions in off-
spring, with mixed results. One more recent study found
that higher levels of the sum of omega-3 LCPUFA (DHA,
EPA and docosapentaenoic acid [DPA, 22:5n-3]) in breast
milk at 1 month postpartum were associated with lower
prevalence of parent-reported eczema and clinically-
diagnosed AD at 2 years and food sensitization to cow’s
milk, egg, or peanut at 1 year [31].
An RCT of preterm infants evaluated effects of maternal
supplementation with high-DHA tuna oil or placebo during
lactation through expected date of delivery [32••]. Tuna oil
increased breast milk DHA from 0.25 % of fatty acids to
0.85 % [33]. Bronchopulmonary dysplasia was significantly
reduced in the high DHA group among boys and among all
infants with birthweight <1,250 g. Risk of hay fever for
boys at 12 months and for all infants and for boys at either
12 or 18 months was significantly lower in the high DHA
group, but no differences were found for asthma, eczema, or
food allergy.
LCPUFA Supply Post-Weaning
When foods other than breast milk are introduced into the
diet, children may receive omega-3 LCPUFA through infant
or other formulas, supplements such as fish oil, or fish.
Recent studies assessing effects of consumption of fish or
other LCPUFA sources by infants or children on respiratory
illnesses are summarized in Table 2.
Fish Consumption
Associations between introduction of fish intake and atopic
diseases were assessed in a large prospective cohort of
children. Introduction of fish to the diet before 9 months
of age had a beneficial effect on prevalence of AD [34••].
Follow-up at 4.5 years showed that early fish introduction
was associated with reduced risk of recurrent wheeze [35]
and allergic rhinitis [36]. A separate, smaller birth cohort
study showed that earlier fish introduction was associated
with lower frequency during the first 18 months for AD,
food allergy, and asthma, although the latter did not reach
significance [37].
Another prospective birth cohort study also found a pro-
tective effect of fish consumption, showing that more fre-
quent fish consumption at 1 year of age was associated with
reduced AD prevalence at 2 years [38]. Fish consumption
did not reduce incidence of asthma, but overall prevalence
of asthma, as expected, was very low at 2 years. This study
did not find a protective effect of cod liver oil, suggesting
that there may be protective components in fish other than
LCPUFA. A prospective birth cohort study of children at
high risk for type 1 diabetes found that fish introduction
before 6 months reduced prevalence of allergic rhinitis at
5 years [39•], similar to an earlier study that reported that
fish consumption in the first year significantly reduced the
odds ratio for allergic rhinitis [40]. AD at 6 months was
associated with later asthma and allergic rhinitis [39•].
Clinical Trials of LCPUFA Supply
Few studies have specifically investigated effects of LCPUFA
addition to infant formula on respiratory illnesses and atopic
diseases. Retrospective medical chart reviews were conducted
through 3 years of age for infants previously participating in
two double-blind RCTs [2••]. In these RCTs, infants were fed
control infant formula with no LCPUFA or formula with
0.32–0.36 % of fatty acids as DHA and 0.64–0.72 % ARA
through 12 months of age. The group fed DHA/ARA formula
had significantly lower incidence and odds ratios for
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wheezing/asthma, wheezing/asthma/AD, any allergy, and
URI during the first 3 years than the control group. The
DHA/ARA group also had significantly shorter time to first
diagnosis of wheezing/asthma, wheezing/asthma/AD, any al-
lergy, and URI. Thus, infants fed DHA/ARA formula had
delayed onset as well as lower incidence of common allergic
diseases and URI. No differences were found for otitis media
or combined nonallergic respiratory illnesses (URI, otitis me-
dia, sinusitis, bronchitis, bronchiolitis, and pneumonia).
Preliminary data from a very recent prospective observa-
tional study also found that infants fed an infant formula
with 0.32 % DHA and 0.64 % ARA had significantly lower
incidence of respiratory and allergic illnesses compared to
those fed control formula with no LCPUFA [41]. This study
confirms findings from an earlier observational study that
showed significantly lower incidence of bronchitis/bron-
chiolitis at 5, 7, and 9 months of age in infants fed formula
with these levels of DHA and ARA, compared to formulas
Table 2 Characteristics of studies evaluating the effects of post-weaning consumption of LCPUFA on respiratory and related outcomes in infants
or young children
Author, year (Ref) Type of trial;
location
Subjects Intervention Duration Outcomes evaluated





8,176 infants None Follow-up to 12
months of age
Questionnaires at 6 and 12 months of age on
family, environment, food introduction, and
medical symptoms including food allergy and
atopic dermatitis






8,176 infants None Follow-up to
4.5 years of age
Additional questionnaires at 4.5 years of age on
family, environment, feeding habits, and
medical symptoms including wheezing






8,176 infants None Follow-up to
4.5 years of age
Additional questionnaires at 4.5 years of age on
family, environment, feeding habits, and









None Follow-up to 18
months of age
Parent interviews of feeding practices and allergy
symptoms at 6 and 12 months of age; clinical
and laboratory examination for allergy
diagnoses at 18 months of age





3,086 infants None Follow-up to 2
years of age
Parent questionnaire at 1 year of age on diet and
other exposure in pregnancy through 1 year,








risk of type 1
diabetes
None Follow-up to 5
years of age
Dietary questionnaires at 3, 6, 12, and 24 months
of age; questionnaire on history and symptoms
of asthma, allergic rhinitis, and atopic
dermatitis at 5 years of age












fed from first week
of life




Medical diagnosis of atopic symptoms and











280 mg DHA and
110 mg EPA per
day from fish oil
Birth to 6 months
of age; follow-up to
12 months of age
Plasma and erythrocyte fatty acids and ex vivo
immune responses to allergens at 6 months of
age; allergic diseases at 6 and 12 months of
age; sensitization (by skin prick test) at 12














Change in plasma and erythrocyte fatty acids;
assessment of usual DHA intakes; adverse
events including incidence of illnesses,
including respiratory illnesses, from medical
records and parent reportsDHA-130: toddler
formula with









180 children 9 to 12
years of age
Omega-3 group: milk
drink with 200 mg
EPA and 1 g DHA
from fish oil
Milk drinks fed
5 days per week
for 6 months
Episodes and duration of illnesses during
intervention; plasma phosphatidylcholine
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with lower levels of or no LCPUFA [42]. In addition, the
group fed formula with 0.32 % DHA and 0.64 % ARA had
lower incidence of rhinitis at 1 month and URI at 1 and
12 months [42].
A recent double-blind RCT investigated effects of fish oil
supplementation, providing 280 mg DHA and 110 mg EPA
daily versus placebo, from birth until 6 months on AD and
allergic sensitization in infants at high risk of allergy [43].
There were no significant effects on AD at 6 or 12 months,
although there was reduced Th2 cytokine (IL-13) response
to house dust mite allergen in the fish oil group, associated
with lower AD at 6 and 12 months. Fish oil was also
associated with a significant increase in Th1 cytokine (IFNγ
and TNFα) response. This study had inadequate blinding
and low adherence for the fish oil, so clinical outcomes in
relationship to plasma and erythrocyte fatty acid levels were
evaluated independently of allocation. This analysis showed
a negative correlation between plasma DHA and develop-
ment of AD, which was consistently associated with lower
Th2 cytokines (IL-13 and IL-5) responses, further support-
ing the hypothesis that DHA sufficiency reduces risk of
developing allergy.
A double-blind RCT in children 18–36 months old re-
ceiving either a milk-based toddler formula providing
130 mg (high DHA) or 43 mg algal DHA daily or a control
formula without DHA for 2 months found lower incidence
of respiratory illnesses, including cough, URI, pharyngitis,
bronchitis, pneumonia, and strep throat, in the high DHA
group [44•]; 46 % of children in the control group had at
least one respiratory event, compared with 17 % in the high-
DHA group. The incidence of respiratory illnesses was 41 %
for the group receiving formula providing 43 mg DHA
daily, which was not statistically different from the high-
DHA or control groups.
Another double-blind RCT randomized 9- to 12-year-old
children to receive milk with either added fish oil (providing
200 mg EPA and 1 g DHA daily, 5 days/week for 6 months)
or soy oil [45••]. Fewer subjects in the group fed milk with
fish oil had illnesses, of which URIs (including rhinitis,
colds, and influenza) and diarrhea were most common.
The fish oil group also had fewer episodes of illness per
subject and shorter duration of illnesses.
Discussion
All studies in this review evaluated possible roles for dietary
omega-3 LCPUFA in immune-related outcomes, particular-
ly related to respiratory health. Some, but not all, studies
included only subjects at high risk of allergy. Dietary sour-
ces for LCPUFA, however, varied widely among studies,
including fish, fish or algal oil, breast milk, and milk-based
formulas with added LCPUFA. Levels of intake of specific
LCPUFA also varied widely. All studies included DHA, and
many included EPA, but only trials with infant formula
specifically included ARA. Breast milk and fish oil also
contain other LCPUFA, and fish contributes other nutrients
that impact immune function. Thus, it is not possible to say
what specific LCPUFA, combination of LCPUFA, source(s)
or level(s) provide optimal effects on respiratory health.
Recent studies investigating increased intake of fish, fish
oil, or DHA during pregnancy found inconsistent effects,
with two studies showing no effects [26, 29], and three
showing protective effects of omega-3 LCPUFA supply on
respiratory illnesses [23•] or AD [24, 27, 28] in offspring. A
2005 review concluded that there is strong evidence that
exposure to adequate omega-3 LCPUFA in utero and via
breast milk is associated with reduced development of atop-
ic disease in infants and children [22]. Positive findings
from interventions during pregnancy cannot be ascribed
exclusively to in utero exposure for breastfed infants, as
higher LCPUFA intakes in pregnancy, especially from ha-
bitual diets, can contribute to higher LCPUFA in breast milk
and thus also increase infant LCPUFA supply postnatally.
Postnatal LCPUFA intake, from breast milk, fish, fish oil,
or infant formula with LCPUFA, also has potential to influ-
ence development of allergies and respiratory illnesses.
While several studies found positive effects of earlier intro-
duction of fish on respiratory allergies or other aspects of
atopy [34••, 35–38, 39•], the effect could be related to
factors other than omega-3 LCPUFA present in fish. Several
RCTs, however, specifically assessed LCPUFA addition to
infant formula and milk-based beverages for children. Two
RCTs in children that evaluated dietary DHA and EPA from
fish oil [45••] or DHA from algal oil [44•] found significant
reductions in incidence of overall illnesses (primarily URI)
or respiratory illnesses, demonstrating a benefit specific to
omega-3 LCPUFA. Birch et al. [2••] found that addition of
DHA in combination with ARA to infant formula has pos-
itive effects on not only URI but also allergic manifesta-
tions, including wheezing/asthma; similar results for
respiratory infections and allergy were seen in two prospec-
tive observational studies [41, 42].
Higher omega-3 LCPUFA in breast milk has also been
associated with less asthma, AD, and food sensitizations
[31, 46, 47], and maternal supplementation during lactation
reduced incidence of respiratory illnesses in preterm infants
[32••]. In a cohort of infants at high risk of allergy, however,
associations were found between total omega-3 LCPUFA,
DPA, and DHA in colostrum and risk of sensitization to
food at 6 months and to aeroallergens at 2 years of age [48,
49]. Total omega-3 and ALA in mature breast milk were
associated with non-atopic eczema at 2 years, and total
omega-6, LA and di-homo-γ-linolenic acid (20:3n-6) in
colostrum were associated with allergic rhinitis at 7 years.
One hypothesis underlying associations between DHA and
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ARA precursors and increased allergy might be that im-
paired precursor conversion to LCPUFA, especially DHA,
results in a tissue DHA deficiency that may facilitate atopic
manifestations.
The rate-limiting enzymes in LCPUFA synthesis are the
Δ5 and Δ6 desaturases encoded by the FADS1 FADS2 gene
cluster, and some studies have found relationships between
FADS gene variants and immune-related outcomes [50].
Variability in plasma phospholipid ARA status can be
explained to a very high degree by genetic variants for FADS
1 FADS 2 (28 % in one study), while only 1–3 % of the
variability in DHA status was explained [51]; in this study,
carriers of minor alleles, associated with lower levels of the
LCPUFA products of the desaturases, had lower preva-
lence of allergic rhinitis and AD (not significant after
correction for multiple testing). A recent study found
that children homozygous or heterozygous for the mi-
nor allele who were exclusively breastfed for at least
3 months had lower risk of asthma than those breastfed
for shorter periods, while length of breastfeeding had
no effect on risk of asthma in children homozygous for
the major allele [52]. In addition, women have been
shown to have higher rates of DHA synthesis than men
[53], which may help explain differences in immune
outcomes between genders [32••].
A prevalent hypothesis links excess intake of omega-6
PUFA to increased risk for atopic disease, in part because
ARA, which is present in high concentrations in cell mem-
branes of immune cells, is the precursor for a family of eicos-
anoid mediators that are predominantly pro-inflammatory [20].
A recent review of fatty acid status and atopic disease, howev-
er, did not find clear support for that hypothesis, and the
authors suggest that, given some reports of low ARA status
associated with allergy, combining some omega-6 LCPUFA
with increased omega-3 LCPUFA might prove more effica-
cious against atopic manifestations than omega-3 LCPUFA
alone [54]. Breast milk always contains both omega-3 and
omega-6 LCPUFA, albeit at variable levels and ratios, and
expert recommendations for LCPUFA in infant formula spec-
ify that both DHA and ARA should be added [16, 17]. The
levels and ratio for DHA and ARA are important in the infant
diet because of beneficial effects on neurocognitive develop-
ment [16], and this balance may also be important for the
developing immune system early in life. A study in a mouse
model of AD did not find any effect of ARA or DHA alone on
severity of dermatitis, but found significant improvements with
the 2:1 combination of ARA:DHA [55]. In preterm infants,
lower blood DHA in the first month postnatally was associated
with higher risk of chronic lung disease, while lower blood
ARAwas associated with higher risk of late-onset sepsis [56].
While the optimal levels and ratios of LCPUFA in the infant
diet for immune development and respiratory health cannot be
defined based on currently available data, three recent infant
formula studies found that levels of DHA and ARA
similar to worldwide means in breast milk resulted in
significant reductions in respiratory illness and allergy
early in life [2••, 16, 41, 42].
The omega-3 LCPUFA EPA and DHA can partially
replace ARA in immune cell membranes, and also serve as
precursors for metabolites with potent anti-inflammatory or
inflammation resolution effects, and, thus, are thought to
counterbalance the pro-inflammatory effects of ARA prod-
ucts. This is an overly simplified view, however, both with
regard to the roles for omega-6 versus omega-3 LCPUFA in
immune function and inflammation, as well as the mecha-
nisms involved [11, 57]. For example, ARA gives rise to
PGE2, which has both pro- and anti-inflammatory activity
[57]. Furthermore, ARA can be metabolized into lipoxin A4,
an inflammation-resolving eicosanoid [58].
EPA and especially DHA have been shown to have
multiple mechanisms for effects on immune function. The
omega-3 LCPUFA are metabolized into resolvins and pro-
tectins with anti-inflammatory and inflammation-resolving
actions [58]. For example, protectin D1 (PD1), a product of
DHA shown to be present at lower levels in asthmatic
patients compared to healthy individuals, reduces allergic
pulmonary inflammation [59]. PD1 and resolvin D1, also
derived from DHA, inhibit production of pro-inflammatory
cytokines such as IL-1β, TNFα, and IFNγ [58]. EPA and
DHA can inhibit activation of NF-κB, either directly via a
yet unknown mechanism, or indirectly as a ligand of PPAR-
γ, and further reduce production of pro-inflammatory cyto-
kines [60, 61]. The omega-3 LCPUFA are converted into
DHA- and EPA-containing endocannabinoids with anti-
inflammatory activity [62], but may also decrease produc-
tion of ARA-derived endocannabinoids such as ananda-
mide, which is also immunosuppressive [63]. DHA and
EPA can exert anti-inflammatory effects via G protein-
coupled receptor 120 in macrophages, inhibiting TLR and
TNFα pro-inflammatory signaling pathways [64]. Omega-3
LCPUFA may also impact B-cell function by increasing
membrane order and the size of membrane sphingolipid/
cholesterol-rich lipid rafts, with DHA showing greater
effects than EPA in some models [65].
Overall, most potential mechanisms of DHA and EPA
activity are associated with inhibition and/or resolution
of inflammation, which is consistent with the clinical
studies showing that inflammatory conditions like asth-
ma or AD may be reduced or prevented by omega-3
LCPUFA [11]. The role of ARA in supporting inflam-
mation necessary for host defense, in combination with
active resolution of inflammation via metabolites of
DHA, EPA and ARA, may help explain the lower
incidence of respiratory infections when infants are fed
formula with both omega-6 and omega-3 LCPUFA [2••,
41, 42].
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Conclusions
While extensive research has examined effects of omega-3
LCPUFA early in life on allergic and infectious respiratory
health outcomes, there is great variability across study
designs, contributing to inconsistent results. Of the recent
studies reviewed, most, but not all, found beneficial effects
of fish or other sources of omega-3 LCPUFA on respiratory
outcomes, including reductions in asthma and other allergy
manifestations or markers. Some studies, including RCTs of
fish oil or DHA supplementation of pregnant women or
children, as well as studies of infant formulas with DHA
and ARA, also found reductions in respiratory infections.
Data on the multiple mechanisms by which LCPUFA im-
pact immune function and development provide new
insights into the possible roles of LCPUFA in initiation
and resolution of inflammation. Further research should be
targeted to define optimal dietary sources and amounts of
LCPUFA for specific age groups to support respiratory
health and immune development in the neonate, throughout
childhood, and beyond.
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